(Q35680546)

9 August 2017

title

Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials (English)

1 reference

9 August 2017

Sean P Curtis

1

1 reference

9 August 2017

Jennifer Ng

2

1 reference

9 August 2017

Qinfen Yu

3

1 reference

9 August 2017

Sumiko Shingo

4

1 reference

9 August 2017

Gina Bergman

5

1 reference

9 August 2017

Calogera L McCormick

6

1 reference

9 August 2017

Alise S Reicin

7

1 reference

9 August 2017

publication date

1 January 2004

1 reference

9 August 2017

published in

Clinical Therapeutics

1 reference

9 August 2017

volume

26

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

70-83

1 reference

Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Nonsteroidal anti-inflammatory drugs: effects on kidney function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

1 reference

7 January 2021

Renal effects of COX-2-selective inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Effects of celecoxib and naproxen on renal function in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Acute renal failure related to high-dose celecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Selective COX-2 inhibitors and nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Cyclooxygenase inhibition and thrombogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

Nonsteroidal anti-inflammatory drug nephrotoxicity. Should we be concerned?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

NSAIDS and nephrotoxicity in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

NSAIDs and the elderly. Toxicity and economic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990007-0

7 January 2021

10.1016/S0149-2918(04)90007-0

Identifiers

DOI

1 reference

9 August 2017

1 reference